NovoCure Ltd 8-K, filed Apr 13, 2022
NovoCure Ltd (NVCR)
8-K
2022-04-13
For: 2022-04-11
View Original
Added on
April 04, 2026
About this 8-K
NovoCure Ltd filed this 8-K on April 13, 2022, reporting on events of April 11, 2022.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | |||||||||
(Address of Principal Executive Offices) | (Zip Code) | ||||||||||
+44 (0) 15 3475 6700
Registrant's telephone number, including area code
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b)
On April 11, 2022, Sherilyn McCoy, a Director of NovoCure Limited (the "Company") since 2018, notified the Company of her intention not to stand for reelection to the Board of Directors of the Company (the "Board") at the Company's 2022 annual general meeting of shareholders (the "Annual Meeting"), which is currently scheduled for June 8, 2022.
Ms. McCoy's decision not to stand for reelection was not due to any disagreement with the Company, but rather relates to her desire to focus on other professional commitments, and she will continue to serve on the Board until the expiration of her term at the Annual Meeting.
The Company thanks Ms. McCoy for her service and significant contributions to the Company and wishes her the best of luck in her future endeavors.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NovoCure Limited
(Registrant)
Date: April 13, 2022
By: /s/ Ashley Cordova
Name: Ashley Cordova
Title: Chief Financial Officer